Werewolf Therapeutics annual return on equity
2021
2022
2023
2024
2025
Werewolf Therapeutics Return on Equity (ROE) Growth & History (HOWL)
Werewolf Therapeutics's return on equity was −123.88% for fiscal 2025.
View full Werewolf Therapeutics company overviewWerewolf Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −123.88% | −47.55 pp |
| 2024 | 2024-12-31 | −76.33% | −44.35 pp |
| 2023 | 2023-12-31 | −31.98% | +7.14 pp |
| 2022 | 2022-12-31 | −39.12% | +59.93 pp |
| 2021 | 2021-12-31 | −99.05% | — |
Werewolf Therapeutics quarterly return on equity
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 25.76% | +62.17 pp |
| Q1 2026 | 2026-03-31 | −73.13% | −45.45 pp |
| Q4 2025 | 2025-12-31 | −30.80% | −5.74 pp |
| Q3 2025 | 2025-09-30 | −46.06% | −28.82 pp |
| Q2 2025 | 2025-06-30 | −36.41% | −20.84 pp |
| Q1 2025 | 2025-03-31 | −27.68% | −13.54 pp |
| Q4 2024 | 2024-12-31 | −25.07% | −14.34 pp |
| Q3 2024 | 2024-09-30 | −17.24% | −10.07 pp |
| Q2 2024 | 2024-06-30 | −15.57% | −11.31 pp |
| Q1 2024 | 2024-03-31 | −14.14% | −4.30 pp |
| Q4 2023 | 2023-12-31 | −10.73% | −1.31 pp |
| Q3 2023 | 2023-09-30 | −7.17% | +1.99 pp |
| Q2 2023 | 2023-06-30 | −4.25% | +6.59 pp |
| Q1 2023 | 2023-03-31 | −9.85% | +0.66 pp |
| Q4 2022 | 2022-12-31 | −9.42% | +1.68 pp |
| Q3 2022 | 2022-09-30 | −9.16% | −1.32 pp |
| Q2 2022 | 2022-06-30 | −10.84% | +67.72 pp |
| Q1 2022 | 2022-03-31 | −10.51% | — |
| Q4 2021 | 2021-12-31 | −11.10% | — |
| Q3 2021 | 2021-09-30 | −7.84% | — |
| Q2 2021 | 2021-06-30 | −78.56% | — |
Werewolf Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Werewolf Therapeutics's return on equity decreased from −99.05% to −123.88%, a change of −24.83 percentage points. The latest reported quarter, Q2 2026, shows 25.76%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Werewolf Therapeutics source filings ↗